McDermott Will & Emery·IP / PATENT

Federal Circuit affirms written description for pharma genus claims

Federal Circuit upheld Exelixis patent spec supported genus claims for crystalline cabozantinib salts by disclosing structural features—chemical name, formula, crystalline form—rejecting polymorph challenge.

written-description-genuspharma-patentsfederal-circuitcrystalline-saltshatch-waxmananda-litigationpatent-invaliditycabozantinib
Read the original firm alert → Saturday, September 12, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.